Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 NerPharMa Approved to Manufacture CTI Drug | Contract Pharma

What are you searching for?

Sign in
Breaking News

NerPharMa Approved to Manufacture CTI Drug

The FDA has completed its inspection of Cell Therapeutics, Inc.’s (CTI) facility at NerPharMa, a pharmaceutical manufacturing company belonging to Nerviano Medical Sciences in Nerviano, Italy.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

The FDA has completed its inspection of Cell Therapeutics, Inc.’s (CTI) facility at NerPharMa, a pharmaceutical manufacturing company belonging to Nerviano Medical Sciences in Nerviano, Italy. FDA found the site in compliance for continued manufacture of CTI’s pixantrone product. CTI’s NDA for pixantrone is currently under review to treat relapsed/refractory aggressive non-Hodgkin’s lymphoma. The FDA is expected to make a final decision on approval by April 23rd.

“FDA approval of the NerPharMa facility to manufacture our drug product is a major milestone in the drug approval process and we are pleased that our manufacturing partner is prepared to provide commercial supplies when pixantrone is approved,” said Craig W. Philips, president of CTI.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters